RY 135.93 1.0106% TD 80.27 0.4882% SHOP 96.65 0.8662% CNR 177.19 0.9802% ENB 48.43 0.9589% CP 118.41 1.7181% BMO 127.36 0.4813% TRI 209.58 1.408% CNQ 105.17 -0.1329% BN 54.28 1.2309% ATD 77.76 2.2351% CSU 3681.53 0.5424% BNS 64.51 0.3578% CM 65.32 -0.1681% SU 53.54 1.0379% TRP 49.19 0.2854% NGT 51.38 -4.3025% WCN 227.86 0.4364% MFC 32.14 1.3241% BCE 45.06 0.5804%
Verizon Communications Inc.
VZ Details
Verizon Communications Inc. (NYSE: VZ) is engaged in providing communications, information and entertainment products and services. Its operating segments are 1) Verizon Consumer Group which provides wireless and wireline communications services primarily to individual consumers, and 2) Verizon Business Group, offers wireless services such as data, video, and conferencing services, corporate networking solutions, security and managed network services, local and long-distance phone services, and others to business and government customers and wireline carriers across the US. As of October 19, 2021, the company's market capitalization stood at USD 216.74 billion.
Latest News:
Q2FY21 Results:
Risks:
Outlook:
In FY21, VZ expects YoY growth of 3.5% - 4% in its wireless service revenue, along with an adjusted EPS in the range of USD 5.0 – 5.15. It also expects to incur a capital expenditure of USD 17.5 – 18.5 billion for FY21.
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
VZ Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
VZ's share price has decreased 10.34% in the past six months and is currently leaning towards the lower end of its 52-week range of USD 50.86 to USD 61.95. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 38.30. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 61.39.
Considering the correction in the stock price in the past nine months, encouraging outlook, and associated risks, we recommend a "Buy" rating on the stock at the closing price of USD 52.35, down 0.85% as of October 19, 2021.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
* Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.
Zimmer Biomet Holdings, Inc,
ZBH Details
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a company that develops, manufactures, and sells orthopedic reconstructive goods such as sports medicine, biologics, extremities and trauma products, and other related items. In the United States, Europe, and Japan. ZBH has the largest share of the reconstructive market. The company's market value was USD 31.10 billion on October 19, 2021.
Latest News:
H1FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
ZBH Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
ZBH' share price has fallen 14.32% in the past six months and is currently leaning towards the mid-band of the 52-week range of USD 130.05 to USD 180.36. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 54.75. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 175.62.
Considering the significant dip in the stock price, strong track record, constant dividend yield, improvement in profitability margin, associated risks, and current valuation, we recommend a "Buy" rating on the stock at the closing price of USD 148.92, up 2.72% as of October 19, 2021.
*All forecasted figures and Industry Information have been taken from REFINITIV.
*The reference data in this report has been partly sourced from REFINITIV.
* Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached or if the price closes below the support level.
Disclaimer
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.